Lucentis ranibizumab regulatory update

The U.K.'s NICE issued a final appraisal determination recommending Lucentis ranibizumab from Novartis to treat macular edema secondary to central retinal vein occlusion (CRVO) and for macular edema

Read the full 285 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE